

10/554152
JC09 Rec'd PCT/PTO 22 OCT 2005


PATENT
ATTORNEY'S DOCKET NO.: NBG-110

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Daniela Fattori et al.
Serial No.: Not Assigned
Filed: October 21, 2005
For: NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS
AND FORMULATIONS CONTAINING THEM
Examiner: Not Assigned
Art Unit: Not Assigned

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. §1.10

The undersigned hereby certifies that this document is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 in an envelope addressed to the: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on October 21, 2005.



Mark D. Lorusso

Commissioner for Patents
PO BOX 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the applicants request consideration of this information disclosure statement.

Compliance with 37 C.F.R. §1.97

This information disclosure statement has been filed before the mailing of a first office action on the merits. No fee or certification is required.

Information Cited

The applicants hereby make of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the relative importance of the references.

Remarks

Pursuant to 37 C.F.R. § 1.98(a)(2)(i), copies of non-U.S. patent references are enclosed unless otherwise indicated on the attached form PTO-1449 (modified). A copy of an International Search Report in which the references are identified and their relevance highlighted is also enclosed. It is respectfully requested that:

- The examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- The enclosed form PTO-1449 be signed by the examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- The citations for the information be printed on any patent which issues from this application.

By submitting this information disclosure statement, the applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this information disclosure statement, the applicants make no representation that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this information disclosure statement, the applicants make no

-3-

representation that the information cited in the statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is understood by applicants that the foregoing information will be considered and, to the extent deemed appropriate by the examiner, will be reflected in the examiner's communication.

Respectfully submitted,


Mark D. Lorusso
Reg. No. 41,955
Lorusso & Associates
15 Rye Street, Suite 312
Portsmouth, NH 03801
Tel: (603) 427-0070
Attorneys for Applicants

Docket No.: NBG-102

Date: October 21, 2005

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Docket Number (Optional) NBG-110	Application Number 107554152 JC09 Rec'd PCT/PTO 22 OCT 2005			
				Applicant(s) FATTORI, ET AL.				
				Filing Date N/A	Group Art Unit N/A			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
REF	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	Translation	
							YES	NO
	WO 95/19966	7/27/1995	ITALY		C07D	209/42	✓	
	WO 94/13694	6/23/1994	ITALY		C07K	5/02	✓	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		*International Search Report; I.Goss-Authorized Officer; 8/24/2004. *XP-001006033; Improved Discriminatory properties between human and murine tachykinin HK, receptors of MEN 10930: a new potent and competitive antagonist; M.Astolfi, R.Patacchini, M.Maggi, S.Manzini; 6.1.1997; p. 373-379. *XP-008004494; Rational Design of High Affinity Tachykinin HK2 Receptor Antagonists; S.Boyle, S.Guard, J.Hodgson, D.C. Horwell, W.Howson, J.Hughes, A.McKnight, K.Martin, M.C.Pritchard, K.J.Watling and G.N.Woodruff; 1/6/1994; p.101-113.						
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								